The Conundrum of Anticoagulation for Hospitalized Patients with Covid-19.
NEJM Evid
; 2(2): EVIDe2200329, 2023 Feb.
Article
in En
| MEDLINE
| ID: mdl-38320043
ABSTRACT
Thrombosis in patients with coronavirus disease 2019 (Covid-19) is driven by complex interactions between immune, complement, fibrinolytic, endothelial, and coagulation systems.1 In addition to venous thromboembolism (VTE), microthrombi have also been implicated in contributing to end-organ damage, such as acute respiratory distress syndrome and kidney dysfunction, as well as to overall mortality.1 As available therapies, variants, and vaccines have evolved, so have reported rates of VTE attributable to Covid-19.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thrombosis
/
Venous Thromboembolism
/
COVID-19
Limits:
Humans
Language:
En
Journal:
NEJM Evid
Year:
2023
Document type:
Article